Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has shared an update.
EBR Systems, Inc. has announced the enrollment of the first two patients in its WiSE-UP post-approval study, which aims to collect real-world evidence on the effectiveness of the WiSE left ventricular endocardial pacing system for cardiac resynchronization therapy. This significant milestone involves tracking over 300 patients across 50 US centers over five years, providing valuable insights into both short- and long-term outcomes. The study is expected to enhance the understanding of CRT applications and improve standards of care for heart failure patients, thereby strengthening EBR Systems’ position in the cardiac rhythm management industry.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Silicon Valley-based EBR Systems, Inc. is a company focused on the treatment of cardiac rhythm diseases through its innovative wireless cardiac pacing technology. Their proprietary WiSE technology aims to eliminate the need for traditional cardiac pacing leads, which are often associated with complications and reliability issues. The company’s initial product targets heart failure patients requiring Cardiac Resynchronization Therapy (CRT), with future products potentially addressing other cardiac and non-cardiac indications.
Average Trading Volume: 659,415
Technical Sentiment Signal: Sell
Current Market Cap: A$514.7M
For an in-depth examination of EBR stock, go to TipRanks’ Overview page.